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ORIGINAL ARTICLE
Identiﬁcation of a plasma signature of psychotic disorder
in children and adolescents from the Avon Longitudinal
Study of Parents and Children (ALSPAC) cohort
A O’Gorman1,2, T Suvitaival3, L Ahonen3, M Cannon1, S Zammit4,5, G Lewis6, HM Roche7, I Mattila3, T Hyotylainen3,8, M Oresic3,9,10,
L Brennan2,11 and DR Cotter1,11
The identiﬁcation of an early biomarker of psychotic disorder is important as early treatment is associated with improved patient
outcome. Metabolomic and lipidomic approaches in combination with multivariate statistical analysis were applied to identify
plasma alterations in children (age 11) (38 cases vs 67 controls) and adolescents (age 18) (36 cases vs 117 controls) preceeding or
coincident with the development of psychotic disorder (PD) at age 18 in the Avon Longitudinal Study of Parents and Children
(ALSPAC). Overall, 179 lipids were identiﬁed at age 11, with 32 found to be signiﬁcantly altered between the control and PD groups.
Following correction for multiple comparisons, 8 of these lipids remained signiﬁcant (lysophosphatidlycholines (LPCs) LPC(18:1),
LPC(18:2), LPC(20:3); phosphatidlycholines (PCs) PC(32:2; PC(34:2), PC(36:4), PC(0-34-3) and sphingomyelin (SM) SM(d18:1/24:0)), all
of which were elevated in the PD group. At age 18, 23 lipids were signiﬁcantly different between the control and PD groups,
although none remained signiﬁcant following correction for multiple comparisons. In conclusion, the ﬁndings indicate that the
lipidome is altered in the blood during childhood, long before the development of psychotic disorder. LPCs in particular are
elevated in those who develop PD, indicating inﬂammatory abnormalities and altered phospholipid metabolism. These ﬁndings
were not found at age 18, suggesting there may be ongoing alterations in the pathophysiological processes from prodrome to
onset of PD.
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INTRODUCTION
Psychotic disorders (PD) are among the most severe and
debilitating medical diseases, with schizophrenia being the most
common, affecting ~ 0.51% of the global population.1 At present,
the diagnosis of PD is subjective and there are no reliable
biological diagnostic tests.2 Over the last decade, the psychosis
ﬁeld of research has shifted its focus to the prodrome or at-risk
mental state (ARMS) in an attempt to identify and treat subjects
at high risk of developing a psychotic illness. Investigations have
indicated that 2030% of these individuals will go on to develop
schizophrenia over a 23 year period.3 Strong evidence supports
early intervention as a means to alleviate and improve therapeutic
outcome for individuals.4,5 Owing to the multifactorial complexity
of PD,2,6 the identiﬁcation of a disease signature and molecular
biomarker(s) sensitive to the underlying pathogenic factors would
be of great importance to assist in early detection and diagnosis7
but also to understand the mechanisms underlying the disease
process, which has yet to be fully elucidated.8
Metabolomics, the global study of metabolites in cells, tissues or
bioﬂuids has emerged in recent years as a promising tool to
identify abnormalities in psychotic illnesses. Metabolomic studies
in schizophrenia and related psychoses have highlighted a
number of metabolic perturbations such as glucoregulatory
processes,9,10 fatty acid and lipid metabolism,1113 mitochondrial
function,14 and proline7 and tryptophan metabolism.15 Although a
comprehensive mapping of disturbances in metabolic pathways in
PD is still a long way off,16 the most consistent ﬁndings involve
pathways common to fatty acids and the pro-oxidant/antioxidant
balance.17 A recent study by Rice and colleagues reported
decreased levels of erythrocyte polyunsaturated fatty acid (PUFA)
levels in young people at ultra-high risk of PD,18 providing addi-
tional evidence of the putative ω− 3 PUFA deﬁciency syndrome.
These studies have identiﬁed various metabolite signatures and
have contributed to a developing and enhanced understanding of
the disease mechanism. However, they generally focus on the
adult population who have already transitioned to schizophrenia,
with a majority being medicated, and so they are limited in terms
of identifying early biomarker signatures of the disease.
The aim of this study was to apply metabolomic approaches to
identify plasma alterations in children (age 11) and adolescents
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(age 18) in the ALSPAC cohort who developed PD at age 18. Such
alterations may serve as potential early metabolic signatures/
biomarkers.
MATERIALS AND METHODS
Study cohort
The study comprises individuals from the Avon Longitudinal Study of
Parents and Children (ALSPAC) cohort. The ALSPAC cohort is a prospective
general population cohort, and a rich resource of demographic, environ-
mental and clinical data on the individuals involved.19 The initial cohort
consisted of 14 062 births. Written informed consent was obtained prior to
taking the plasma samples. Ethical approval for the study was obtained
from the ALSPAC Ethics and Law Committee and the Local Royal College of
Surgeons in Ireland (RCSI) Research Ethics Committees. Please note that
the study website contains details of all the data that are available through
a fully searchable data dictionary (http://www.bristol.ac.uk/alspac/research
ers/access).
Measures of psychotic experiences and psychotic disorder. Psychotic
experiences (PE) were identiﬁed at 11 and 18 years through the face-to-
face, semi-structured Psychosis-Like Symptom (PLIKS) interview20 con-
ducted by trained psychology graduates in assessment clinics, and were
coded according to the deﬁnitions and rating rules for the Schedules for
Clinical Assessment in Neuropsychiatry, Version 2.0 (Organisation 1994).
Interviewers rated PEs as not present, suspected or deﬁnitely psychotic.
Cases of psychotic disorder (PD) were deﬁned as individuals with deﬁnite
PEs that were not attributable to the effects of sleep or fever and when the
PE occurred at least once per month over the past 6 months and caused
severe distress, had a very negative effect on social/occupational function,
or led to help seeking from a professional source.20 Control samples from
age-matched individuals without suspected or deﬁnite PEs, or PD at age 18
were randomly selected to match cases (Table 1).
Plasma availability in age 11 samples
We identiﬁed 38 individuals with PD at age 18 (cases) who had plasma
samples at age 11 available for the metabolomic/lipidomic analysis.
Control samples (n=67) from age and body mass index (BMI)-matched
individuals without suspected or deﬁnite PEs at age 11, or PD at age 18
were randomly selected to match cases (Table 1).
Plasma availability in age 18 samples
We identiﬁed 36 individuals with PD at age 18 (cases) who had
plasma samples at age 18 available for the metabolomic/lipidomic
analysis. Control samples (n= 117) from age and BMI-matched
individuals who did not have PD at age 18, or suspected or deﬁnite PEs
at age 11 were randomly selected to match cases (Table 1). Of the PD
cases, 25 individuals plasma samples were present at both age 11 and 18.
Therefore, considering that there were 38 PD samples at age 11, and 36 PD
samples at age 18, overall there were a total of 49 individual PD subjects
studied.
Plasma sample collection
Non-fasting (age 11) and fasting (age 18) blood samples were collected
from the participants into heparin Sarstedt S-Monovette tubes (Sarstedt,
Numbrecht, Germany), stored on ice for a maximum of 90 min until
processed. Post centrifugation, the plasma samples were stored at − 80 °C
until further analyses.
Global lipidomic analysis
The plasma samples were analysed for global proﬁling of lipids using a
method developed speciﬁcally for lipidomics analyses. The samples were
prepared following the previously published Folch procedure21 with minor
modiﬁcations. Brieﬂy, 10 μl of 0.9% NaCl, 100 μl of CHCl3:MeOH (2:1, v/v)
and 20 μl of a 3.5 μg ml− 1 working standard solution of chosen lipid
standards (for quality control and data normalisation purposes) were
added to 10 μl of each plasma sample. The standard solution contained
the following compounds: 1,2-diheptadecanoyl-sn-glycero-3-phos-
phoethanolamine (PE(17:0/17:0)), N-heptadecanoyl-D-erythro-sphingosyl-
phosphorylcholine (SM(d18:1/17:0)), N-heptadecanoyl-D-erythro-
sphingosine (Cer(d18:1/17:0)), 1,2-diheptadecanoyl-sn-glycero-3-phospho-
choline (PC(17:0/17:0)), 1-heptadecanoyl-2-hydroxy-sn-glycero-3-phospho-
choline (LPC(17:0)) and 1-palmitoyl-d31-2-oleoyl-sn-glycero-3-
phosphocholine (PC(16:0/d31/18:1)). These were purchased from Avanti
Polar Lipids (Alabaster, AL, USA). In addition, 1,2-dimyristoyl-sn-glycero-3-
phospho(choline-d13) (PC(14:0/d13)) was purchased from Sigma Aldrich
(Wicklow, Ireland) and Tripalmitin-1,1,1-13C3 (TG(16:0/16:0/16:0)-13C3) and
Trioctanoin-1,1,1− 13C3 (TG(8:0/8:0/8:0)− 13C3) from Larodan (Solna,
Sweden) for the same purpose. The samples were vortex mixed and
allowed to stand on ice for 30 min after which they were centrifuged
(9400 g, 3 min, 4 °C). Overall, 60 μl from the lower layer of each sample was
then transferred to a glass vial with an insert and 60 μl of CHCl3:MeOH (2:1,
v/v) was added. The samples were then stored at − 80 °C until analysis.
Calibration curves (at concentration levels of 100, 500, 1000, 1500, 2000
and 2500 ng ml− 1) for quantiﬁcation of lipids were prepared using 1-
hexadecyl-2-(9Z-octadecenoyl)-sn-glycero-3-phosphocholine (PC(16:0e/
18:1(9Z))), 1-(1Z-octadecenyl)-2-(9Z-octadecenoyl)-sn-glycero-3-phospho-
choline (PC(18:0p/18:1(9Z))), 1-octadecanoyl-sn-glycero-3-phosphocholine
(LPC(18:0)), 1-(1Z-octadecenyl)-2-docosahexaenoyl-sn-glycero-3-phospho-
choline (PC(18:0p/22:6)), 1-stearoyl-2-arachidonoyl-sn-glycero-3-phosphoi-
nositol (PI(18:0/20:4)) and 1-stearoyl-2-linoleoyl-sn-glycerol (DG(18:0/20:4))
from Avanti Polar Lipids, 1-Palmitoyl-2-Hydroxy-sn-Glycero-3-Phosphati-
dylcholine (LPC(16:0)) from Larodan, and 1,2,3-Triheptadecanoylglycerol
(TG(17:0/17:0/17:0)) and 3β-hydroxy-5-cholestene 3-linoleate (ChoE(18:2))
from Sigma Aldrich.
The samples were analysed using an ultra-high-performance liquid
chromatography quadrupole time-of-ﬂight mass spectrometry method
(UHPLC-Q-TOF-MS). The UHPLC system was a 1290 Inﬁnity system from
Agilent Technologies (Santa Clara, CA, USA), which was equipped with a
multisampler (maintained at 10 °C) using 10% DCM in MeOH and ACN:
MeOH:IPA:H2O (1:1:1:1, v/v/v/v)+0.1% HCOOH as needle wash solutions
after each injection for 7.5 s each, a quaternary solvent manager and a
column thermostat (maintained at 50 °C). Separations were performed on
an ACQUITY UPLC BEH C18 column (2.1 mm×100 mm, particle size
1.7 μm) by Waters (Milford, CT, USA). The ﬂow rate was 0.4 ml min− 1 and
the injection volume was 1 μl. H2O+1% NH4Ac (1M)+0.1% HCOOH (A) and
ACN:IPA (1:1, v/v)+1% NH4Ac+0.1% HCOOH (B) were used as the mobile
phases for the gradient elution. The gradient was as follows: from 0 to
2 min 3580% B, from 2 to 7 min 80100% B and from 7 to 14 min 100% B.
Each run was followed by a 7 min re-equilibration period under initial
conditions (35% B). The mass spectrometer was a 6550 iFunnel quadrupole
time-of-ﬂight (Q-TOF) from Agilent Technologies (Agilent) interfaced with a
dual jet stream electrospray (dual ESI) ion source. Nitrogen generated by a
nitrogen generator (PEAK Scientiﬁc, Renfrewshire, Scotland, UK) was used
as the nebulising gas at a pressure of 21 psi, as the drying gas at a ﬂow rate
of 14l min− 1 (at 193 °C) and as the sheath gas at a ﬂow rate of 11l min− 1
(at 379 °C). Pure nitrogen (6.0) from Praxair (Fredericia, Denmark) was used
as the collision gas. The capillary voltage and the nozzle voltage were kept
at 3643 and 1500 V, respectively. The reference mass solution including
ions at m/z 121.0509 and 922.0098 was prepared according to instructions
by Agilent and it was introduced to the mass spectrometer through the
Table 1. An overview of the ALSPAC study population characteristics
Controls age 11
(n=67)
Cases age 11
(n=38)
Controls age 18
(n=117)
Cases age 18
(n=36)
BMI± s.d. 17.73± 2.53 18.2± 3.36 22.69± 3.51 23.12± 3.74
Male:female 39M: 28F 8M:30F 58M:59F 8M:28F
Abbreviations: BMI, body mass index; s.d., standard deviation.
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other nebuliser in the dual ESI ion source using a separate Agilent series
1290 isocratic pump at a constant ﬂow rate of 4 ml min− 1 (split to 1:100
before the nebuliser). The acquisition mass range was m/z 1001700 and
the instrument was run using the extended dynamic range with an
approximate resolution of 30 000 FWHM measured at m/z 1521.9715
(which is included in the tune mixture) during calibration of the
instrument. MassHunters B.06.01 (Agilent) software was used for all data
acquisition.
Quality control was performed throughout the dataset by including
blanks, pure standard samples, extracted standard samples and control
plasma samples. Relative standard deviations (%RSDs) for retention times
and peak areas for lipid standards representing each lipid class in the
plasma samples and in the pure standard samples were calculated. The %
RSDs for the retention times were on average 0.1% for both the plasma
samples and for the pure standards samples. The %RSDs for the peak areas
were within accepted analytical limits at averages of 17.5 and 16.6% for the
plasma samples and for the pure standard samples, respectively. This
shows that the method is reliable and repeatable throughout the
sample set.
Lipidomic data were pre-processed with MZmine 2 and peaks were
identiﬁed based on the internal peak library. Peak areas were normalised
by lipid class-speciﬁc internal standards and quantiﬁed with R based on
the inverse-weighted linear model. Internal standard peaks were detected
in a targeted way from the standards runs. The internal MS librarys
retention times were corrected with R to match the study with a linear
correction based on the observed retention times in the standards runs.
Other peaks in the sample runs were processed in a non-targeted way as:
import of the mzML ﬁles, mass detection, chromatogram builder,
chromatogram deconvolution, isotopic peak grouper, peak ﬁlter, peak list
row ﬁlter, join aligner, peak list row ﬁlter, gap ﬁlling, peak list ﬁlter,
identiﬁcation with custom data base search. The peak table was ﬁltered in
R, allowing the peak to be missing in each of the eight batches in a
maximum 50% of the samples. Remaining missing values were imputed
with feature-wise half-the-minimum. All lipid metabolites, that were
present (non-zero value) in more than 75% of samples were included in
the data analyses.
Global metabolomic analysis
Polar metabolites were analysed in the plasma samples using compre-
hensive two-dimensional gas chromatography combined with time-of-
ﬂight mass spectrometry (GC×GC-TOFMS, a LECO Pegasus 4D equipped
with a cryogenic modulator from LECO, St. Joseph, MI, USA). Speciﬁcally,
400 μl methanol and 10 μl internal standard mixture heptadecanoic acid
(175 mg l− 1), DL-valine-d8 (36 mg l− 1), succinic acid-d4 (59 mg l− 1) and DL-
glutamic acid-d5 (110 mg l− 1) were added to 30 μl of plasma samples. The
samples were vortex mixed and centrifuged for 5 min at 10 000 r.p.m. and
half of the supernatant was evaporated to dryness. This was followed by
two step derivatisation using methoximation and silylation. Speciﬁcally, the
samples were derivatised by adding ﬁrst 25 μl methoxamine MOX (45 °C,
60 min) and then 25 μl N-trimethylsilyl-N-methyl triﬂuoroacetamide MSTFA
(45 °C, 60 min). Finally, 50 μl of a retention index standard mixture (n-
alkanes, c=8 mg l− 1) with an injection standard (4,4-dibromooctaﬂuor-
obiphenyl, c= 10 mg l− 1), both in hexane, was added to the mixture. The
calibration consisted of six points for each quantiﬁed metabolite.
The columns were as follows: a methyl deactivated retention gap
(1.5 m× 0.53 mm i.d.) was connected to 10 m×0.18 mm Rtx-5 (i.d.
diameter 0.18 mm, dfphase thickness 0.20 μm) and to 1.5 m×0.1 mm
BPX-50 (i.d. 0.1 mm, dfphase thickness 0.1 μm). Helium was used as the
carrier gas at a constant pressure mode (40psig). A 4 s separation time was
used in the second dimension. The temperature programme was as
follows for the ﬁrst-dimension column: 50 °C (2 min), at 7 °C min− 1 to
240 °C and at 25 °C min− 1 to 300 °C (3 min). The second-dimension
column temperature was 15 °C higher than the corresponding ﬁrst-
dimension column throughout the programme.
The analytical method used allows for combined targeted and
untargeted analysis, where a selected subset of metabolites can be
quantiﬁed. In the present study, quantitation of 23 target metabolites
(stearic acid, oleic acid, linoleic acid, palmitic acid, citric acid, glutamic acid,
3,4-dihydroxybutanoic acid, 3-hydroxybutyric acid, 2,4-dihydroxybutanoic
acid, threonine, phenylalanine, serine, lactic acid, methionine, glycine,
isoleucine, leucine, valine, proline, 2-hydroxybutyric acid, cholesterol,
arachidonic acid and alanine) was done by external calibration curves for
each individual metabolite.
ChromaTOF vendor software (LECO) was used for within-sample data
processing, and the Guineu software (https://code.google.com/p/guineu/)
was used for alignment, normalisation and peak matching across
samples.22 The normalisation was performed by correction for internal
standards and speciﬁc target metabolites were additionally quantiﬁed
using external calibration curves. Other mass spectra from the GC×GC-
TOFMS analysis were searched against the NIST 14 Mass Spectral Library
and Golm Metabolome Database,23 using also retention index data in the
identiﬁcation. Artefact peaks due to chemical background and compounds
outside the linear range of the method were removed from the dataset.
Control serum samples (n=32 for human) and pure standards (to monitor
the instrument performance and robustness) were analysed together with
the samples. The relative standard deviation (RSD) for internal standards,
spiked into the samples, was on average of 15.7% for the plasma samples.
The RSD% of the quantiﬁed metabolites in the control serum samples
(n=32) was on average 23.4%. The RSD% was 13.3% for isoleucine, 11.2%
for leucine and 24.2% for valine in control serum samples (n= 4), and for
internal standards in mice serum the RSD was on average 16.6%. Neither
sample preparation nor analysis order showed any signiﬁcant effect on the
results.
All plasma metabolite peaks that were present (non-zero value) in more
than 75% of samples were included in the data analyses, including the
unidentiﬁed ones. The unidentiﬁed peaks were annotated with their
structural class from the Golm Metabolome Database using functional
group prediction based on the fragmentation patterns.22,23
Targeted metabolomic analysis
A targeted metabolomic approach was taken to target a speciﬁc metabolic
pathway, that is, the tricarboxylic acid (TCA) cycle (citric acid, succinic acid,
fumaric acid, malic acid, α-ketoglutaric acid). A subset of control samples at
both ages 11 and 18 were used for the analysis. This resulted in the
following study numbers: PD at age 11 (38 controls vs 38 cases) and PD at
age 18 (36 controls vs 36 cases) (Supplementary Table 4). Brieﬂy, 50 μl of
0.1 mg ml− 1 of Labelled internal standards (succininc acid-2,2,3,3-d4,
fumaric acid-2,3-d2, adipic acid-2,2,5,5-d4 and DL-malic acid-2,3,3-d3, Sigma
Aldrich) were added to 100 μl of plasma. To this, 440 μl of anhydrous EtOH,
100 μl pyridine, 500 μl of deionised H2O and 150 μl of ethylchloroformate
(ECF) was added and samples were vortexed. To this, 1000 μl of CHCl3 was
added. The pH was then adjusted to 56 by adding 7M NaOH solution and
shaken for 5 s. Overall, 100 μl of ECF was added and vortexed for 20 s. To
this, 2 ml of deionised H2O was added and vortexed. The samples were
then centrifuged at 1700 g for 3 min at 4 °C. The CHCl3 layer was
transferred to a 10 ml glass tube containing anhydrous sodium sulphate
drying reagent. Following drying, samples were analysed using an Agilent
7200 Q-TOF GC/MS system (Agilent, Santa Clara, CA, USA).
Calibration was achieved by comparison of metabolite peak areas with
reference to an external standard (TCA cycle metabolite library, Sigma
Aldrich) and by comparison of their mass spectra with those in the NIST
library (version 2.0). For quality control purposes, an aliquot from a pool of
plasma was extracted and analysed in parallel with each batch of samples.
Quantiﬁcation of the TCA metabolites was carried out using the
Masshunter TOF quantitative analysis software (version B.07.01, Agilent).
Statistical analyses
Censored regression analysis (SAS, version 9.3, Cary, NC, USA) was applied
to the datasets to identify signiﬁcant differences (Po0.05) in lipid and
metabolite levels between the control and PD groups at both age groups,
adjusting for gender and BMI. Signiﬁcant lipids and metabolites were
corrected for multiple comparisons using the BenjaminiHochberg step-up
procedure in R (version 3.2.2) (Po0.1). Censored regression analysis was
applied as the majority of lipids and metabolite levels were not normal-
distributed and were reported in varying concentration ranges among
participants. Individual lipid levels were visualised using the beanplot
algorithm implemented in R. A beanplot gives information on the mean
lipid level within each group, the density of the data-point distribution and
illustrates individual data points.11 Cluster analysis was performed using
the Mclust package24 in R (version 3.2.2), which uses Gaussian mixture
modelling ﬁtted via the expectation-maximisation (EM) algorithm for
model-based clustering.24 Prior to clustering, the data were normalised
using a logarithmic transformation.
For the targeted metabolomic analysis, metabolite levels between
groups were compared using general linear models gender and BMI as
covariates (SPSS version 20, IBM, Armonk, NY, USA).
Plasma signature of psychotic disorder in children
A OGorman et al
3
Translational Psychiatry (2017), 1  9
The levels of the lipids in the PD case group were analysed relative to
the control group as a function of the acyl chain length and double bond
content within each lipid group. The level ratio was computed by ﬁrst
computing each lipids average level within each subject group, and the
computing the ratio of these average levels between the PD case and the
control groups. Each lipids level ratio was shown on the y-axis of two lipid
group-speciﬁc ﬁgures for each time point: one with the number of carbon
atoms in the lipids acyl chain on the x axis and another with the number
of double bonds in the lipids acyl chain on the x axis. These ﬁgures were
used for the qualitative evaluation of changes in the lipids that could be
related to the chain length and level of saturation.
RESULTS
The ﬁnal lipidomic datasets used for analysis included a total of
179 lipids from the following lipid classes: cholesterol esters (CEs),
lysophosphatidlycholines (LPCs), phosphatidlycholines (PCs),
phosphatidylethanolamines (PEs), sphingomyelins (SMs), triglycer-
ides (TGs), a diacylglycerol (DG) and a phosphatidylinositol (PI).
Age 11 and 18 lipidomic signatures of PD
At age 11, a total of 32 lipids were signiﬁcantly altered between
controls and cases (nominal P-value o0.05). These lipids included
three CEs, ﬁve LPCs, 19 PCs, four SM and a TG (Table 2). All of these
lipids, with the exception of TG(56:7), were elevated in the PD
group. Eight of these passed FDR signiﬁcance (P-value o0.1)
(Figure 1). Relationships with the acyl chain length of lipid species
was examined (Figures 2 and 3; Supplementary Figure 1). LPCs of
lower carbon numbers and double bond content were higher in
the PD group. An upward sloping relationship was seen in the
mean ratio of SM levels in cases vs controls for higher carbon
numbers. Clear patterns are not seen for the PCs and TGs,
although the ﬁgure does highlight that the PCs are elevated in the
PD group and TGs are downregulated, particularly so for those
with a lower number of carbon double bonds.
The global lipidome was then evaluated by clustering the data
into a set of lipid clusters. Cluster analysis identiﬁed seven lipid
clusters (LC) and a description of each cluster is given in Table 3.
Three of the identiﬁed clusters were signiﬁcantly higher in the PD
case group. LC4 was dominated by LPCs (P-value = 0.025), LC6 was
dominated by both PCs and CEs (P-value = 0.036), whereas LC7
was a cluster containing PCs (P-value = 0.006).
At age 18, a total of 23 lipids were signiﬁcantly different
between the control and PD groups (Table 4; nominal P-value
o0.05). These lipids were three LPCs, thirteen PCs, one PE, three
SMs and three TGs. All of these lipids, with the exception of PC
(36:4), were decreased in the PD group (Figure 2), although no
clear pattern with respect to the acyl carbon chain length
or double bond content was observed. The lipid cluster LC4
was signiﬁcantly decreased in the PD group (P-value = 0.017)
and was dominated by LPCs (Supplementary Table 1). None of
these however passed signiﬁcance at the selected FDR threshold
of 0.1.
Age 11 and 18 polar metabolomic signatures of PD
The metabolomic datasets used for analysis contained a total of
151 metabolites. At the age of 11, a total of 8 metabolites were
signiﬁcantly different between the control and PD groups, 6 of
which were signiﬁcantly decreased (1-monopalmitin, 2,3-dihy-
droxybutanoic acid, D-(− )-ribofuranose, ethanolamine, hydroxyla-
mine and ribitol) and two signiﬁcantly elevated (sugar derivatives)
Table 2. Differential plasma lipids between control and PD groups at age 11
Lipid name Control (n=67) Cases (n= 38) P-value FDR-adjusted
CE(18:2) 13481.42± 4506.22 15773.88± 3728.61 0.0392 0.242
CE(18:2)+unknown CE (667.6219) 6568.58± 2222.39 7967.17± 2181.29 0.0313 0.2391
LPC(16:1) 38.27± 5.84 41.23± 7.13 0.0119 0.1776
LPC(18:1) 231.84± 63.24 268.76± 77.1 0.0028 0.0972
LPC(18:2) 394.75± 128.23 502.39± 181.49 o0.0001 0.0179
LPC(20:3) 37.21± 6.83 41.1± 8.13 0.0003 0.0269
LPC(20:4) 63.03± 14.89 66.84± 15.93 0.0246 0.2282
PC(16:0e/18:1(9Z)) 92± 29.94 105.2± 28.8 0.0368 0.2391
PC(30:0) 56.88± 16.51 65.36± 23.83 0.0165 0.1981
PC(32:0) 175.51± 39.91 200.61± 38.49 0.0083 0.1486
PC(32:1) 238.88± 90.72 288.76± 113.49 0.0231 0.2282
PC(32:2) 61.56± 20.85 72.75± 21.5 0.0027 0.0972
PC(34:2) 3759.47± 717.83 4257.93± 741.34 0.0065 0.0972
PC(36:2) 2940.24± 630.99 3360.9± 623.41 0.0125 0.1776
PC(36:3) 1753.26± 669.47 2152.76± 569.66 0.0349 0.2391
PC(36:4 404.62± 165.27 504.24± 198.32 0.0038 0.0972
PC(38:2) 70.5± 22.97 81.8± 22.28 0.0244 0.2282
PC(38:4) 36.07± 10.37 40.94± 10.62 0.0374 0.2391
PC(40:6) 56.74± 20.41 64.26± 17.7 0.0357 0.2391
PC(O-32:0) 49.78± 11.18 55.84± 11.43 0.0078 0.1486
PC(O-32:1) 37.88± 7.19 40.82± 7.11 0.0353 0.2391
PC(O-34:2) 85.95± 27.42 98.13± 30.17 0.0255 0.2282
PC(O-34:3) 111.62± 33.27 132.51± 36.51 0.0036 0.0972
PC(O-36:2) 51.25± 15.7 57.48± 14.77 0.0166 0.1981
PC(O-36:3) 42.86± 11.11 47.38± 11.72 0.0277 0.2361
PC(O-38:6) 74.25± 23.67 84.11± 22.81 0.0455 0.2627
SM(d18:0/16:0) 829.78± 212.45 933.75± 194.41 0.0129 0.1776
SM(d18:1/24:0) 6167.04± 2537.94 7281.12± 2418.58 0.0029 0.0972
SM(d41:1) 3540.52± 1381.32 3889.15± 1148.96 0.0419 0.25
SM(d42:2) 15796± 5875.87 18218.69± 5133.36 0.0339 0.2391
TG(56:7) 103.59± 97.25 76.17± 46.64 0.0198 0.2215
Abbreviations: CE, cholesterol ester; LPC, lysophosphatidylcholine; PC, phosphatidylcholine; PD, psychotic disorder; SM, sphingomyelin; TG, triacylglycerol. Values
are expressed as standard units± s.d. (standard deviation). P-values are adjusted for gender and BMI. FDR-adjusted P-values are adjusted for multiple
comparisons using the Benjamini–Hochberg procedure. Values in bold are lipids that remain signiﬁcant (Po0.1) folllowing correction for multiple comparisons.
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Figure 1. The levels of signiﬁcant lipids at FDR level for age 11 samples.
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Figure 2. The relationship between psychotic disorder and acyl chain content in lipid species. The mean ratio of lipid levels in cases vs controls
in plasma samples (ages 11 and 18) for lysophosphatidlycholines (LPCs).
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in the PD group (Table 5), although none were signiﬁcant at the
selected FDR threshold. Cluster analysis identiﬁed six metabolite
clusters (CL), none of which were signiﬁcant between study
groups (Supplementary Table 2).
At the age of 18, a total of 19 metabolites were signiﬁcantly
different between the case and control groups, none at FDR level
(Table 6). These metabolites mainly belonged to the following
classes of metabolites; organic acids, fatty acids and sugar/sugar
derivatives and were all signiﬁcantly decreased in the PD group
with the exception of glycine and levoglucosan which were
elevated in the PD group. 1-Monopalmitin is the only common
signiﬁcant metabolite between the studies and was found to be
decreased in PD groups at both ages. The metabolite cluster CL1
was signiﬁcantly decreased in the PD group (P-value = 0.034) and
contained 22 metabolites consisting of fatty acids, organic acids
and unknown metabolites (Supplementary Table 3).
Targeted analysis of the TCA cycle metabolites revealed no
signiﬁcant difference between the study groups at the ages of 11
and 18. At the age of 18, succinic acid was signiﬁcantly decreased
in the PD group (P-value = 0.04) (Table 7).
DISCUSSION
Our ﬁndings indicate that the lipidome is altered between
subjects with PD compared to subjects who do not experience
any PEs, particularly at the age of 11, giving promise to the
potential of an early biomarker signature of PD. At the age of 11, a
number of LPCs were found to be signiﬁcantly elevated in the PD
group. This is indicative of altered phospholipid metabolism,
which has been considered as the pathophysiological basis of
schizophrenia for some time.13 A number of studies have reported
impaired phospholipid levels in schizophrenia subjects, although
the speciﬁc results have not been consistent.
LPC, an inﬂammatory phospholipid generated by hydrolysis of
PC via the actions of phospholipase A2 (PLA2), promotes
inﬂammatory effects such as expression of endothelial cell
adhesion molecules, growth factors, chemotaxis and activation
of monocytes/macrophages.25 LPC has been suggested to have a
functional role in the pathogenesis of various diseases including
atherosclerosis,26 diabetes27 and systematic autoimmune
diseases.28 The association between inﬂammatory abnormalities
and PD has been found repeatedly in many studies, which
reported increased levels of pro-inﬂammatory compounds (mainly
cytokines) in the serum, plasma and cerebrospinal ﬂuid of patients
with psychosis29 or who transition to schizophrenia from the at-
risk mental state.30 In support of the inﬂammatory theory in
relation to psychotic outcome in the ALSPAC cohort, Khandaker
et al.31 reported higher levels of the systematic inﬂammatory
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Figure 3. The relationship between psychotic disorder and acyl chain content in sphingomyelins (SMs). The mean ratio of lipid levels in cases
vs controls in plasma samples (ages 11 and 18) for SMs.
Table 3. Description of lipid clusters obtained from lipidomics
platform in the age 11 cohort and evaluated across the study groups
Cluster name Cluster size Cluster description P-value (controls vs
cases)
LC1 12 TGs 0.255
LC2 44 TGs 0.966
LC3 8 LPCs 0.025
LC4 29 PCs and TGs 0.96
LC5 23 PCs and SM 0.054
LC6 40 PCs and CEs 0.036
LC7 20 PCs 0.006
Abbreviations: CEs, cholesterol esters; LC, lipid cluster; LPCs, lysopho-
sphatidylcholines; PCs, phosphatidylcholines; SM, sphingomyelins; TGs,
triacylclycerols. Values in bold are lipid clusters (LC) that are signiﬁcant
between controls vs cases (Po0.05).
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cytokine marker IL-6 in childhood, which was associated with an
increased risk of developing psychosis in young adulthood.
Lipidomic studies have previously identiﬁed elevated plasma
levels of LPCs (16:0, 18:0, 18:1 and 18:2) in ﬁrst-episode neuroleptic
naive schizophrenia patients as compared to healthy controls.12 Of
the reported signiﬁcant LPCs, two were also signiﬁcantly elevated
in this study at the age of 11 (LPC 18:1 and LPC 18:2), which
suggests that LPCs with lower carbon numbers and fewer double
bonds are associated with risk of PD. An earlier study reported
increased platelet membrane LPC in schizophrenia patients.32
However, there are inconsistencies in studies, with one study
reporting diminished levels of LPCs in the serum of schizophrenia
patients compared to their co-twins as well as healthy controls.11
Furthermore, there are some noteworthy difference between this
study and previous ones, particularly relating to the age of the
subjects and the diagnosis. The samples studied in the current
investigation were donated from participants at the ages 11 and
18 and were thus very different in terms of medication exposure
and duration of psychotic illness from those of ﬁrst episode or
chronic schizophrenia. In comparison, the mean age of ﬁrst-
episode schizophrenia patients in the study by Cai and colleagues
was 27.5 ±9.5 years (n= 11). In the twin study, which involved twin
pairs discordant for schizophrenia, the participants had an average
age of 51 years (n= 19), with the majority taking antipsychotic
medication. The differences between these studies could explain
some of the inconsistencies in the reported ﬁndings related to the
direction of the LPCs and also highlights the need for validation
studies for biomarker conﬁrmation. Identiﬁcation of the biomar-
kers at a young age prior to conversion to schizophrenia would be
of more beneﬁt clinically to assist early detection and diagnosis.7
A total of four PCs were found to be signiﬁcantly elevated in the
plasma of the PD group at age 11. At age 18, the PCs were
decreased in the PD group, although not signiﬁcant at the
selected FDR threshold. A few studies have reported PCs to be
related to psychotic outcome, with most of the studies reporting
reduced levels in schizophrenia.33,34 The ﬁnding of elevated LPCs
and PCs at age 11 and subsequent decreased levels relative to the
controls (although not signiﬁcant at FDR level) at age 18 suggest
Table 4. Differential plasma lipids between control and PD groups at age 18
Lipid name Control (n=117) Cases (n=36) P-value FDR-adjusted
LPC(16:0) 848.58± 191.96 771.44± 227.83 0.0402 0.4042
LPC(16:1) 37.75± 6.43 35.03± 5.67 0.0319 0.3609
LPC(22:6) 28.63± 4.66 25.7± 4.46 0.0255 0.4196
PC(31:0) 26.39± 7.66 22.9± 7.38 0.0136 0.4103
PC(32:1) 281.87± 137.89 249.65± 106.1 0.0311 0.3752
PC(33:1) 62.63± 18.43 54.06± 13.57 0.0037 0.2232
PC(35:1) 75.59± 21.09 68.31± 13.57 0.0405 0.3858
PC(36:2) 67.41± 21.4S 62.37± 16.45 0.0468 0.385
PC(36:4) 2641.06± 637.15 2656.62± 708.18 0.0369 0.3929
PC(37:4) 67.93± 26.92 59.57± 28.94 0.0456 0.4127
PC(38:6) 114.34 ± 42.33 109.33± 32.87 0.0122 0.4416
PC(40:6) 283.19± 122.05 255.9± 115.8 0.031 0.4008
PC(40:7) 76± 27.51 68.99± 23.89 0.0147 0.3801
PC(O-38:4) 100.79± 36.03 85.19± 33.38 0.0213 0.4283
PC(O-40:6) 34.75± 6.81 32.08± 6.39 0.0169 0.3823
PC(O-42:3) 29.63± 6.56 26.94± 7.07 0.047 0.3699
PE(P-18:0/22:6) 35.6± 8.05 32.61± 7.62 0.0466 0.4016
SM(d18:0/16:0) 890.9± 207.12 850.9± 189.57 0.0118 0.534
SM(d32:1) 1901.22± 547.7 1783.34± 498.81 0.0259 0.3907
SM(d33:1) 1227.82± 311.1 1118.09± 297.23 0.003 0.2715
TG(49:3) 33.78± 1.18 33.31± 1.53 0.0242 0.438
TG(51:2) 26.14± 3.26 24.06± 5.41 0.0024 0.4344
TG(56:7) 106.1± 58.84 95.83± 76.34 0.0288 0.401
Abbreviations: CE, cholesterol ester; LPC, lysophosphatidylcholine; PC, phosphatidylcholine; PD, psychotic disorder; SM, sphingomyelin; TG, triacylglycerol.
Values are expressed as standard units± s.d. (standard deviation). P-values are adjusted for gender and BMI. FDR-adjusted P-values are adjusted for multiple
comparisons using the Benjamini–Hochberg procedure.
Table 5. Differential plasma metabolites between control and PD groups at age 11
Metabolite name Control (n= 67) Cases (n=38) P-value FDR-adjusted
1-monopalmitin 448.89± 162 368.91± 123.4 0.0128 0.544
2,4-Dihydroxybutanoic acid 0.09± 0.03 0.07± 0.02 0.014 0.544
D-(− )-ribofuranose 98.34±169.78 52.87± 40.02 0.0429 0.7
Ethanolamine 250.51± 88.88 214.15± 46.75 0.0215 0.544
Ribitol 175.9± 41.79 155.67± 31.77 0.0202 0.544
Hydroxylamine 88.11± 38.61 66.9± 39.02 0.0043 0.544
Sugar derivative 805.27± 247.15 961.92± 337.63 0.0274 0.591
Sugar derivative 89.91± 74.69 141.94± 85.59 0.0216 0.544
Abbreviations: BMI, body mass index; FDR, false discovery rate; PD, psychotic disorder. Values are expressed as standard units± s.d. (standard deviation).
P-values are adjusted for gender and BMI. FDR-adjusted P-values are adjusted for multiple comparisons using the Benjamini–Hochberg procedure.
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that biomarker proﬁles may change with age. Furthermore, it
suggests that the pathophysiological process can alter over time
and with proximity to disease onset.35 A similar ﬁnding was
reported in type 1 diabetes where increased LPCs were identiﬁed
in children who later progressed to the disease. Following
seroconversion to autoantibody positivity, the metabolic proﬁles
of the participants were partially normalised, indicating that early
biomarkers may be useful in diabetes prevention strategies.36 It
has been suggested elsewhere that maybe the ideal biomarkers
are involved in aetiological pathways and are subsequently likely
to change according to disease status.37
In terms of the metabolome, very few metabolite differences
were identiﬁed between control and PD groups (ages 11 and 18),
with none signiﬁcant at FDR level. 1-monopalmitin was reported
to be decreased in the PD group at both ages and is a lipid
implicated in membrane integrity and stability and an energy
storage source.38 Citric acid and succinic acid (targeted metabo-
lomic approach) were found to be reduced in the PD group at age
18. A number of previous studies have reported citric/citrate acid
levels to be reduced in serum and urine samples in schizophrenia
patients, with one study ﬁnding elevated levels in serum in a
schizophrenia cohort, indicating a compromised energy
metabolism.12,16 Decreased levels of citric acid and succinic acid
indicate a dysfunction in TCA cycle activity and a deﬁcit in
mitochondrial respiration.16 A study comparing healthy controls vs
schizophrenia pre-frontal cortex tissue reported that aerobic
energy pathways were signiﬁcantly decreased with reduced
protein and transcript expression of TCA and oxidative phosphor-
ylation enzymes,14 conﬁrming compromised energy metabolism
in individuals with schizophrenia.3941
A major strength of this investigation is the ALSPAC cohort upon
which it was based. The ALSPAC cohort includes detailed long-
itudinal clinical assessments and biosampling. The plasma samples
were collected at age 11, prior to the development of psychotic
disorder, and were not subject to confounds of drug exposure and
chronic illness. Our observation of an altered lipidome at age 11,
therefore, highlights a perturbed metabolism related to inﬂamma-
tion in the PD group, which may be an early biomarker signature of
the disease, with the LPCs representing potential future early
biomarkers of PD. The detected associations indicate that lipidomic
proﬁles are useful for identifying important disease signatures.
However, as a step to move these signatures closer to utilisation in
the clinic validation in an external cohort is necessary. Notwith-
standing this, the present study is an important step towards the
identiﬁcation of a signature associated with the development of PD.
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Table 6. Differential plasma metabolites between control and PD groups at age 18
Metabolite name Control (n= 117) Cases (n= 36) P-value FDR-adjusted
1-Monopalmitin 312.8± 129.67 254.3± 112.61 0.012 0.323
2-Hydroxybutyric acid 577.68± 232.1 489.04± 213.93 0.0161 0.323
3-Hydroxybutyric acid 36.64± 37.35 25.76± 23.78 0.0464 0.369
Cholesterol 359.7± 82.18 335.36± 75.08 0.0165 0.323
Citric acid 7.22± 2.98 5.85± 2.36 0.0329 0.346
Glycine 11.52± 3.19 12.07± 3.79 0.0374 0.346
Leucine 13.13± 3.34 11.23± 2.72 0.412 0.346
L-tryptophan 14.95± 7.76 12.12± 8.77 0.0411 0.346
Oleic acid 88.13± 30.34 79.9± 25.78 0.0344 0.346
Palmitic acid 105.31± 23.19 97.2± 16.08 0.0171 0.323
Scyllo-inositol 79.11± 102.3 51.76± 40.75 0.0215 0.325
Stearic acid 35.94± 8.4 32.93± 6.74 0.0275 0.346
Sugar derivative 1666.31± 517.3 1474.28± 530.76 0.0288 0.346
A144004 416± 242.81 314.94± 301.41 0.0125 0.323
Sugar derivative 1253.88± 362.07 1076.74± 395.7 0.0137 0.323
Threonic acid 1457.44± 491.45 1294.07± 599.63 0.02 0.325
Sugar derivative 916.23± 283.49 840.44± 324.57 0.0155 0.323
Tocopherol, α 453.34± 307.71 353.09± 133.91 0.0151 0.323
Levoglucosan 31.55± 52.17 36.39± 51.9 0.0356 0.346
Abbreviations: BMI, body mass index; FDR, false discovery rate; PD, psychotic disorder. Values are expressed as standard units± s.d. (standard deviation). P-
values are adjusted for gender and BMI. FDR-adjusted P-values are adjusted for multiple comparisons using the Benjamini–Hochberg procedure.
Table 7. TCA cycle metabolite differences between study groups at
age 18
Metabolite Controls (n= 36)
(mg l− 1)
Cases (n=36)
(mg l− 1)
P-value
Citric acid 11.68± 5.86 9.43± 4.84 0.07
Succinic acid 0.57± 0.24 0.46± 0.23 0.04
Fumaric acid 0.72± 0.08 0.77± 0.48 0.69
a-ketoglutaric acid 1.06± 0.65 0.87± 0.68 0.24
Malic acid 0.47± 0.47 0.52± 0.47 0.36
Abbreviations: BMI, body mass index; TCA, tricarboxylic acid. P-values are
adjusted for gender and BMI.
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